NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS Stock Report

Market Cap: US$2.4b

NewAmsterdam Pharma Management

Management criteria checks 2/4

NewAmsterdam Pharma's CEO is Michael Davidson, appointed in Aug 2020, has a tenure of 4.33 years. total yearly compensation is $5.81M, comprised of 9.8% salary and 90.2% bonuses, including company stock and options. directly owns 0.89% of the company’s shares, worth $20.87M. The average tenure of the management team and the board of directors is 2.1 years and 2.1 years respectively.

Key information

Michael Davidson

Chief executive officer

US$5.8m

Total compensation

CEO salary percentage9.8%
CEO tenure4.3yrs
CEO ownership0.9%
Management average tenure2.1yrs
Board average tenure2.1yrs

Recent management updates

Recent updates

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Oct 04

Will NewAmsterdam Pharma (NASDAQ:NAMS) Spend Its Cash Wisely?

Oct 01
Will NewAmsterdam Pharma (NASDAQ:NAMS) Spend Its Cash Wisely?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 03
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

CEO Compensation Analysis

How has Michael Davidson's remuneration changed compared to NewAmsterdam Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$199m

Jun 30 2024n/an/a

-US$229m

Mar 31 2024n/an/a

-US$229m

Dec 31 2023US$6mUS$569k

-US$177m

Compensation vs Market: Michael's total compensation ($USD5.81M) is about average for companies of similar size in the US market ($USD5.54M).

Compensation vs Earnings: Insufficient data to compare Michael's compensation with company performance.

CEO

Michael Davidson (68 yo)

4.3yrs

Tenure

US$5,809,158

Compensation

Dr. Michael Harvey Davidson, M.D., FACC., FNLA, serves as Director at Nanophoria S.R.L. since January 2024. Dr. Davidson is a Co-Founder and Chief Scientific Officer of TROFI NUTRITIONALS, INC. He serves a...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Davidson
CEO, President4.3yrsUS$5.81m0.89%
$ 20.9m
Johannes Jacob Kastelein
Founder5.9yrsUS$2.98m0.25%
$ 5.8m
Mayur Somaiya
Chief Financial Officer1.2yrsUS$3.82mno data
Juliette Audet
Chief Business Officerless than a yearUS$45.63k0.0012%
$ 28.0k
Douglas Kling
Chief Operating Officer3.8yrsno data0%
$ 0
Louise Kooij
Chief Accounting Officer1.2yrsno data0%
$ 0
Matthew Philippe
Executive VP &Head of Investor Relations1.7yrsno datano data
Bob Rambo
Executive Vice President of Marketing1.9yrsno datano data
Marc Ditmarsch
Chief Development Officer2.3yrsno data0%
$ 0
Sheng Cui
Chief Manufacturing Officer3.7yrsno datano data
Annie Neild
Executive VP & Head of Global Regulatory Affairs3.8yrsno datano data
William Jones
Chief Commercial Officer1.3yrsno datano data

2.1yrs

Average Tenure

54yo

Average Age

Experienced Management: NAMS's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Davidson
CEO, President2.1yrsUS$5.81m0.89%
$ 20.9m
Johannes Jacob Kastelein
Founder2.1yrsUS$2.98m0.25%
$ 5.8m
Louis Lange
Independent Non-Executive Director2.1yrsUS$339.05k0.027%
$ 634.4k
James Topper
Non-Executive Director2.1yrsUS$40.00kno data
Christie Ballantyne
Member of Clinical Advisory Boardno datano datano data
William Lewis
Independent Chairman of Board of Directorsless than a yearno datano data
John Smither
Independent Director1.8yrsUS$138.83k0%
$ 0
Wouter Joustra
Non-Executive Directorless than a yearno datano data
Brian Ference
Member of Clinical Advisory Boardno datano datano data
Kosh Ray
Member of Clinical Advisory Boardno datano datano data
Ann Navar
Member of Clinical Advisory Boardno datano datano data
Stephen Nicholls
Member of Clinical Advisory Boardno datano datano data

2.1yrs

Average Tenure

68yo

Average Age

Experienced Board: NAMS's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NewAmsterdam Pharma Company N.V. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Judah FrommerCredit Suisse
Debjit ChattopadhyayGuggenheim Securities, LLC
Yuchen DingJefferies LLC